Related Experiment Videos
[Immunopathogenesis of bronchial asthma]
S Finotto1, P R Galle, M F Neurath
1Labor Immunologie I, I. Medizinische Klinik der Johannes Gutenberg Universität Mainz. finotto@mail.uni-mainz.de
Pneumologie (Stuttgart, Germany)
|November 10, 2000
Summary
Allergic asthma involves inflammation and bronchoconstriction, driven by immune cells and cytokines. Novel therapies targeting these pathways offer potential for more effective asthma treatment than corticosteroids.
Area of Science:
- Immunology
- Pulmonology
- Allergy
Context:
- Allergic asthma is a chronic pulmonary disease characterized by inflammation and bronchoconstriction.
- Mast cells, eosinophils, and T-lymphocytes play key roles in asthma pathogenesis through mediator and cytokine production.
- Increased T-helper 2 (TH2) cytokine production (IL-4, IL-5, IL-13) is a hallmark of allergic asthma.
Purpose:
- To review recent advances in understanding the immunopathogenesis of allergic asthma.
- To explore novel therapeutic strategies based on immunomodulation.
- To assess the potential of new treatments compared to corticosteroids.
Summary:
- Allergic asthma pathogenesis involves inflammatory mediators and cytokines, particularly TH2 cytokines.
- Novel therapies include cytokine-based treatments, oral tolerance induction, IgE inhibitors, and cytokine receptor antagonists.
- These approaches aim for selective suppression of pulmonary inflammation and bronchoconstriction.
Impact:
- Potential for more selective and effective treatment of allergic asthma.
- Highlights the need for further research into the long-term efficacy and safety of immunomodulatory therapies.
- Advances understanding of asthma's immune mechanisms and therapeutic targets.